These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 18416033)

  • 41. [Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)].
    Acevedo W; Gallardo AM; Galaz J; Afani A; Cortés E
    Rev Med Chil; 2007 Nov; 135(11):1406-13. PubMed ID: 18259651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance.
    Maggiolo F; Airoldi M; Callegaro A; Ripamonti D; Gregis G; Quinzan G; Bombana E; Ravasio V; Suter F
    J Int Assoc Physicians AIDS Care (Chic); 2007 Jun; 6(2):87-93. PubMed ID: 17537998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand.
    Apisarnthanarak A; Mundy LM
    Clin Infect Dis; 2008 May; 46(10):1630-1. PubMed ID: 18419506
    [No Abstract]   [Full Text] [Related]  

  • 44. Genotypic Characterization of Human Immunodeficiency Virus Type 1 Derived from Antiretroviral Drug-Treated Individuals Residing in Earthquake-Affected Areas in Nepal.
    Negi BS; Kotaki T; Joshi SK; Bastola A; Nakazawa M; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Sep; 33(9):960-965. PubMed ID: 28298145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong.
    Chen JH; Wong KH; Li PC; Chan KK; Lee MP; To SW; Yam WC
    Hong Kong Med J; 2012 Feb; 18(1):20-4. PubMed ID: 22302906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
    Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA
    AIDS Res Hum Retroviruses; 2016 Sep; 32(9):841-50. PubMed ID: 27346600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations.
    Wang K; Samudrala R; Mittler JE
    J Infect Dis; 2004 Dec; 190(11):2055-6; author reply 2056. PubMed ID: 15529272
    [No Abstract]   [Full Text] [Related]  

  • 49. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan.
    Chang SY; Chen MY; Lee CN; Sun HY; Ko W; Chang SF; Chang KL; Hsieh SM; Sheng WH; Liu WC; Wu CH; Kao CL; Hung CC; Chang SC
    J Antimicrob Chemother; 2008 Mar; 61(3):689-93. PubMed ID: 18227088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
    Vercauteren J; Vandamme AM
    Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [HIV-1 genotypic resistance].
    Vela CM
    An R Acad Nac Med (Madr); 2007; 124(3):465-73; discussion 473-5. PubMed ID: 18416033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.
    Oliveira MI; Romão de Souza Junior V; Fernanda de Lacerda Vidal C; Sérgio Ramos de Araújo P
    BMC Infect Dis; 2018 Oct; 18(1):514. PubMed ID: 30314470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
    Ormaasen V; Sandvik L; Asjø B; Holberg-Petersen M; Gaarder PI; Bruun JN
    HIV Med; 2004 Nov; 5(6):400-6. PubMed ID: 15544691
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.